U.S. Court of Appeals Affirms Novarad’s ‘807 Patent as Company Continues to Defend Leadership in Augmented Reality Surgical Navigation
Summarize this article with:
Author of the article:You can save this article by registering for free here. Or sign-in if you have an account.Ruling reinforces strength of Novarad’s intellectual property as litigation continuesSubscribe now to read the latest news in your city and across Canada.Subscribe now to read the latest news in your city and across Canada.Create an account or sign in to continue with your reading experience.Create an account or sign in to continue with your reading experience.Salt Lake City, Utah, Dec. 15, 2025 (GLOBE NEWSWIRE) — Novarad Corporation, a global leader in medical imaging and immersive augmented reality surgical navigation, today announced that the United States Court of Appeals for the Federal Circuit, one level below the U.S. Supreme Court, has affirmed the decision of the Patent Trial and Appeal Board (PTAB) of the United States Patent and Trademark Office, upholding Novarad’s U.S. Patent No. 10,945,807. Following oral argument, the appeal was terminated on the merits.The decision arises from an ongoing, multi-year litigation effort related to challenges brought by Medivis, Inc., a New York–based company that sought to invalidate two of Novarad’s foundational patents covering augmented reality navigation technologies.Get the latest headlines, breaking news and columns.By signing up you consent to receive the above newsletter from Postmedia Network Inc.A welcome email is on its way. If you don't see it, please check your junk folder.The next issue of Top Stories will soon be in your inbox.We encountered an issue signing you up. Please try againInterested in more newsletters? Browse here.Medivis also did not prevail at the Patent Trial and Appeal Board on all challenged claims of Novarad’s U.S. Patent No. 11,004,271. The Board’s decision in that proceeding is also on appeal at the Federal Circuit, and a ruling in that appeal remains pending.“Strong intellectual property protection is essential to sustaining innovation in augmented reality surgical navigation,” said Michael Chandler, CFO of Novarad. “These decisions reinforce the validity of Novarad’s technology and our commitment to protecting the investments we’ve made in developing clinically revolutionary AR solutions.”Novarad further alleges that Medivis is infringing multiple additional Novarad patents and believes the federal litigation may expand to include additional parties. Patent law extends beyond the unauthorized sale or distribution of protected technologies to include their unauthorized use, which could implicate major hospital systems, including the University of Pittsburgh and MD Anderson.A Global Leader in Augmented Reality Surgical NavigationNovarad, headquartered in Utah with installations at more than a thousand sites worldwide, was the first company to receive FDA clearance for an augmented reality medical system for surgical planning. VisAR, Novarad’s FDA-cleared augmented reality surgical navigation platform, enables surgeons to visualize complex anatomy and guide instruments with unprecedented precision. VisAR is approved for clinical utilization in numerous countries, including the United States, Brazil, Mexico, Australia, New Zealand, Singapore, Indonesia, Vietnam, and the United Arab Emirates, with additional approvals pending.Augmented reality surgical guidance enables clinicians to visualize complex internal anatomy by overlaying three-dimensional digital information directly onto the patient, allowing surgeons to “see through” the body and guide instruments with greater precision during complex procedures.Novarad currently holds approximately 30 U.S. and international patents related to augmented reality navigation. “As we created solutions to complex technical challenges in AR navigation, we filed for patent protection for these truly innovative ideas,” said Dr. Wendell A. Gibby, CEO of Novarad. “This is one of the few technologies where doctors say ‘wow’ each time they see it.”See it at www.novarad.net/visar.Ongoing global interest in augmented reality technologies is reflected in recent announcements from companies such as Meta and Google, which continue to invest in and deploy AR-related platforms—further validating the importance of its role in medical applications that Novarad has helped pioneer.About NovaradNovarad delivers innovative enterprise imaging systems, surgical navigation solutions, and clinical workflow technologies used by healthcare providers around the world. With a multi-decade history of breakthroughs in medical imaging and immersive guidance systems, Novarad is committed to transforming how clinicians visualize and interact with patient data.Learn more at www.novarad.net.Media ContactIan ScottMarketing & Communications, Novaradmarketing@novarad.net(385) 265-1617Postmedia is committed to maintaining a lively but civil forum for discussion. Please keep comments relevant and respectful. Comments may take up to an hour to appear on the site. You will receive an email if there is a reply to your comment, an update to a thread you follow or if a user you follow comments. Visit our Community Guidelines for more information.